Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 5/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.37 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19718237 | 1.00 | MME (0.47) | MMECTSSCTSKCA2CA9 | |
| SCHEMBL9974745 | 0.79 | MME (0.61) | MMECTSSCTSKACESCN9A | |
| SCHEMBL9963896 | 0.79 | MME (0.61) | MMECTSSCTSKACESCN9A | |
| SCHEMBL18597975 | 0.79 | MME (0.61) | MMECTSSCTSKACESCN9A | |
| SCHEMBL9974741 | 0.79 | MME (0.61) | MMECTSSCTSKACESCN9A | |
| SCHEMBL9963897 | 0.77 | MME (0.57) | MMEACEACE2 | |
| SCHEMBL2875959 | 0.77 | MME (0.44) | MMECTSSCTSKCA2CA9 | |
| SCHEMBL20376371 | 0.77 | MME (0.42) | MMECTSSCTSKCA2CA9 | |
| SCHEMBL6177689 | 0.76 | ATM (0.48) | CTSSCTSKCA2CA9ABCB1 | |
| SCHEMBL9966297 | 0.76 | MME (0.53) | MMECTSKACEMMP8SRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-9845332-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845332-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885CTSS 117/4885CTSK 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.